Adjuvant endocrine therapy (AET) is prescribed to women with Stage I–III estrogen receptor–positive breast cancer (around 70%–80% of all breast cancers) for 5–10 years, to reduce breast cancer recurrence and mortality [1, 2]. The gene discussed is ESR1; the disease is breast carcinoma.